---
title: "Editas Medicine ends reni-cel program, cuts about 180 positions (65%"
url: "https://aibio.space/news/editas-medicine-ends-reni-cel-program-cuts-about-180-positions-65/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2024-12-12"
section: "Distress"
tickers: "NASDAQ:EDIT"
source: "https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/edit-20241211.htm"
summary: "The company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now"
---

By the aibio.space news desk.

Sources

- [Editas Medicine, Inc. 8-K (2024-12-12)](https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/edit-20241211.htm)

[EDIT](https://aibio.space/companies/editas-medicine/)

2024-12-12

# Editas Medicine ends reni-cel program, cuts about 180 positions (65% of workforce)

Tickers [EDIT](https://aibio.space/companies/editas-medicine/)

The company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now sees cash lasting into the second quarter of 2027.

## Key facts

- **Company**: Editas Medicine, Inc. (NASDAQ: EDIT)

- **News type**: Distress

- **Primary source**: [Editas Medicine, Inc. 8-K (2024-12-12)](https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/edit-20241211.htm)

*Old law books on library shelves. CC0, via rawpixel. The picture shows the field, not the companies named.*

Editas Medicine, Inc. (Nasdaq: [EDIT](https://aibio.space/companies/editas-medicine/)) said its board approved on December 11, 2024, the discontinuation of clinical development of its reni-cel program for sickle cell disease and transfusion-dependent beta thalassemia. The board also approved a reduction of approximately 180 positions, or approximately 65%, of the workforce. The company says it is acting to extend its cash runway and refocus resources on in vivo pipeline development.

Editas expects to substantially complete the reduction by the end of June 2025. It expects the cost savings to extend its cash runway into the second quarter of 2027.

The company expects to incur approximately $55.0 million to $70.0 million for the discontinuation. That covers wind-down of clinical development activities, including contract termination costs, impairment charges and non-cash charges. It expects another $14.0 million to $18.0 million for the reduction, mostly severance and benefits. Editas says a significant portion of the charges should lead to future cash spending and is already reflected in its runway estimate.

On December 11, 2024, the board also ended the process to partner or out-license reni-cel. Executive Vice President and Chief Medical Officer Baisong Mei will step down effective December 31, 2024. Two directors told the company they intend to resign from the board effective that date.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

EDIT

Editas Medicine, Inc.

NASDAQ · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/editas-medicine-ends-reni-cel-program-cuts-about-180-positions-65/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Editas Medicine ends reni-cel program, cuts about 180 positions (65%", 2024-12-12, https://aibio.space/news/editas-medicine-ends-reni-cel-program-cuts-about-180-positions-65/